Type 2 diabetes mellitus (T2DM) is increasing in prevalence worldwide. The complications associated with T2DM result in increased mortality and financial cost for those affected. T2DM has long been known to be associated with insulin resistance in peripheral tissues and a relative degree of insulin deficiency. However, the concept that insulin secretion and insulin sensitivity are not linked through a hyperbolic relationship in T2DM has continuously been demonstrated in many clinical trials. Thus, in order to prevent and treat T2DM, it is necessary to identify the substance(s) that will improve the function and survival of the pancreatic β-cells in both normal and pathologic conditions, so that production and secretion of insulin can be enhanced. Incretin hormones, such as glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic polypeptide (GIP), have been shown to lower the postprandial and fasting glucose and the glycated hemoglobin levels, suppress the elevated glucagon level, and stimulate glucose-dependent insulin synthesis and secretion. In this report, we will review the biological actions and mechanisms associated with the actions of incretin hormones, GLP-1 and GIP, on β-cell health and compare the differences between GLP-1 and GIP.

Citations

Citations to this article as recorded by  

• A phase I study comparing the pharmacokinetics of the biosimilar (RD12014) with liraglutide (Victoza) in healthy Chinese male subjects
  Ruirui Zhou, Linfeng Guo, Xianglei Gao, Yijun Wang, Wenjing Xu, Yang Zou, Wenjia Li, Yulei Zhuang, Gangyi Liu, Yanmei Liu
  Clinical and Translational Science.2022; 15(10): 2458.     CrossRef
• Misregulation of Wnt Signaling Pathways at the Plasma Membrane in Brain and Metabolic Diseases
  Mustafa Karabicici, Yagmur Azbazdar, Evin Iscan, Gunes Ozhan
  Membranes.2021; 11(11): 844.     CrossRef
• Effects of newly introduced antidiabetic drugs on autophagy
  Milad Ashrafizadeh, Habib Yaribeygi, Stephen L. Atkin, Amirhossein Sahebkar
  Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2019; 13(4): 2445.     CrossRef
• Genistein enhances the secretion of glucagon-like peptide-1 (GLP-1) via downregulation of inflammatory responses
  Kanwal Rehman, Mehwish Bagh Ali, Muhammad Sajid Hamid Akash
  Biomedicine & Pharmacotherapy.2019; 112: 108670.     CrossRef
• Liraglutide vs Exenatide: Patient Adherence, Medication Persistence and Economic Evaluation in the Treatment of Type 2 Diabetes Mellitus
  Fiorenzo Santoleri, Paola Sorice, Ruggero Lasala, Alberto Costantini
  Pharmacology & Pharmacy.2014; 05(04): 332.     CrossRef
• Metformin enhances glucagon-like peptide 1 via cooperation between insulin and Wnt signaling
  Mi-Hyun Kim, Jae-Hwan Jee, Sunyoung Park, Myung-Shik Lee, Kwang-Won Kim, Moon-Kyu Lee
  Journal of Endocrinology.2014; 220(2): 117.     CrossRef
• Predicting the DPP-IV Inhibitory ActivitypIC50Based on Their Physicochemical Properties
  Tianhong Gu, Xiaoyan Yang, Minjie Li, Milin Wu, Qiang Su, Wencong Lu, Yuhui Zhang
  BioMed Research International.2013; 2013: 1.     CrossRef
• Exendin-4 Protects Against Sulfonylurea-Induced β-Cell Apoptosis
  Ju-Young Kim, Dong-Mee Lim, Hyung-Seo Park, Chan-Il Moon, Kyung-Jin Choi, Seong-Kyu Lee, Haing-Woon Baik, Keun-Young Park, Byung-Joon Kim
  Journal of Pharmacological Sciences.2012; 118(1): 65.     CrossRef
• Retrospective Analysis on the Efficacy, Safety and Treatment Failure Group of Sitagliptin for Mean 10-Month Duration
  Won Jun Kim, Cheol-Young Park, Eun Haeng Jeong, Jeong Youn Seo, Ji Soo Seol, Se Eun Park, Eun Jung Rhee, Won Young Lee, Ki Won Oh, Sung Woo Park, Sun Woo Kim
  Diabetes & Metabolism Journal.2011; 35(3): 290.     CrossRef